about
HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically highTrends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment RegimensMutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited settingNext generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South AfricaEarly Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells.Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineEmergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settingsFuture technologies for monitoring HIV drug resistance and cure.Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.Barriers to HIV remission research in low- and middle-income countries.No evidence of HIV replication in children on antiretroviral therapy.Moderate levels of pre-therapy drug resistance (PDR) in a generalised epidemic: time for better first-line ART?Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.Late Onset HIV Encephalopathy in Children with Long-Standing Virologic Suppression Followed by Slow Spontaneous Recovery despite No Change in Antiretroviral Therapy -Four Case Reports.CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.Is HIV-1C a risk factor for protease inhibitor failure?Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa.Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.Irreproducible positive results on the Cobas AmpliPrep/Cobas TaqMan HIV-1 Qual test are different qualitatively from confirmed positive results.Antiretroviral therapy in children with tuberculosis: progress toward defining the issues.Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?Protease inhibitor resistance in South African children with virologic failure.Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa.Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.Extraction buffer contaminated bacterially as a cause of invalid HIV-1 viral load results on the NucliSens EasyQ system.HIV evolution and diversity in ART-treated patients.Rapid decline of HIV-1 DNA and RNA in infants starting very early ART may pose a diagnostic challenge.Paper-based detection of HIV-1 drug resistance using isothermal amplification and an oligonucleotide ligation assay.Adult antiretroviral therapy guidelines 2017.Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots.NucliSens EasyQ® HIV-1 V1.2 system: Detection of human plasma-derived background signalSignificantly Diminished Long-Term Specificity of the BED Capture Enzyme Immunoassay Among Patients With HIV-1 With Very Low CD4 Counts and Those on Antiretroviral TherapyYoung age a predictor of weak reactivity in a rapid antibody test in infants infected with HIV
P50
Q28476627-9FD9CAB9-ABDD-422A-956A-331A6109E5ACQ28534323-6F5596B1-7555-4A90-AE5C-6A5BE329C0D9Q33603586-97097985-F535-405A-82A0-751DC81E3CC7Q34778123-B1210885-47F0-4C65-B794-4008613483D5Q34785616-3E720718-65AB-4102-90EA-4D9C752C09B5Q35156697-48937063-A12D-4D9C-9002-1BFCF05F9200Q35974409-E94B5D45-7432-4D4D-9035-6296A8E00993Q36023047-1DEA19F4-3292-4618-B557-E3C7971596F3Q36669337-5A417418-31D8-412B-8C74-34F3569731D3Q36852626-1E3AF388-7E5E-40EC-9C74-5484D5D8C61AQ37003942-12306F88-2368-4933-B9B0-DB676AB55068Q38774060-DEFCDCEC-6FCC-4216-9670-A9F099FA8CE3Q39125858-BA3C2A5E-E744-4849-BBDB-427D4C05F0FFQ39209322-A042AB5E-BC2C-44C5-A2AF-19F59F2FA131Q39360243-7474C4E5-E07D-48F0-8271-080602BA9F49Q39366791-AB288D0A-BED3-4A3E-9B30-AC875C990410Q40047983-71EC5093-2B2A-442A-81C3-1437D707A8C7Q40063398-729A1403-3E2C-41E2-890A-BB2589909D73Q40104085-AD71A265-6992-46C2-800E-8ADD3410B25DQ40118266-128D6322-ABF6-4E65-8E49-65551C405960Q40301916-123D8E1B-3274-4C1C-AD7C-5D90FFD41900Q40731826-B64AE83D-C54C-46E2-BD4E-02EF7BD54980Q40977735-E635C356-7CCF-4912-BAA1-5A661A702AD6Q42167560-3FA3FDED-7EEF-47A1-8D0A-F8F112FCF395Q42212478-94FB2806-FB06-4E4F-B605-8EADFC0E98A0Q42261541-03C73170-64F8-47C2-A647-2B60F374F85CQ43137225-CF556ED3-1B98-4081-8D4A-A4538D78FA08Q43160854-D2ACDB3C-DC41-4E56-BA47-153FFD6B4841Q43271706-E2E9D0DF-1963-4DA9-9A62-A235B92C5E5CQ44782681-85939FB8-0CE5-4741-B2E3-857EF2728B92Q46160580-4804BF74-A0E5-404E-9CC8-3AFC0C744640Q46226766-2A94DDD7-1997-44B6-B09C-A6146CD0B154Q47548221-C2BB011C-C1A8-470A-B4DF-FB9D8C5B6AA4Q47553584-E9BB7CED-0CAE-4F22-951B-43B54A4F66D0Q47566956-B70831B2-6DF5-4EA6-8B90-07EA87A3CB06Q52641448-FC814B32-AE84-4FB7-85E7-2D037890A0D9Q54332509-6F2A99CB-D80F-4F03-9E4A-6E35D4BE5538Q57083221-92E99EDA-7F76-4B08-85A3-4CF64C1DA862Q57083223-994D968D-DF06-4F79-A3E7-18F6306F512FQ57083224-50FD5C16-7055-4B52-A2AF-9E54372B6C2C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gert U Van Zyl
@ast
Gert U Van Zyl
@en
Gert U Van Zyl
@es
Gert U Van Zyl
@nl
type
label
Gert U Van Zyl
@ast
Gert U Van Zyl
@en
Gert U Van Zyl
@es
Gert U Van Zyl
@nl
prefLabel
Gert U Van Zyl
@ast
Gert U Van Zyl
@en
Gert U Van Zyl
@es
Gert U Van Zyl
@nl
P106
P1153
6602148482
P21
P31
P496
0000-0003-3021-5101